Effects of Cilnidipine, an L/N-Type Calcium Channel Blocker, on Carotid Atherosclerosis in Japanese Post-Stroke Hypertensive Patients: Results from the CA-ATTEND Study
Overview
Authors
Affiliations
Aims: Although several antihypertensive agents reduced the carotid intima-media thickness (IMT), it remains unclear whether those agents affect the interadventitial diameter (IAD). We aimed to examine whether cilnidipine, an L/N-type calcium channel blocker, reduced the common carotid IMT or IAD in post-stroke hypertensive patients.
Methods: The common carotid IMT and IAD were measured at the start of cilnidipine treatment and 12 months from that. The changes in the mean max-IMT or IAD between baseline and the 12-month follow-up were evaluated and compared between the thick group (max-IMT ≥1.1 mm) and the normal group (max-IMT <1.1 mm).
Results: A total of 603 post-stroke hypertensive subjects (mean age=69.3 yr, 378 males) were included in the analysis. At baseline, IAD was increased stepwise according to the value of max-IMT (p for trend <0.001). Among them, 326 subjects were followed up for 12 months. The mean max-IMT from baseline to 12 months did not change in the normal group (-0.01 mm, 95% confidence interval [CI] -0.03 to 0.01, n=170), whereas a significant reduction was observed in the thick group (-0.09 mm, 95% CI -0.13 to -0.05, n=156). The mean IAD was significantly reduced during the study period in the normal group (-0.14 mm, 95% CI -0.22 to -0.05) as well as in the thick group (-0.12 mm, 95% CI -0.21 to -0.03).
Conclusions: Cilnidipine promoted the regression of common carotid IMT in post-stroke hypertensive patients, especially in the thick group. Cilnidipine also reduced the IAD in both normal and thick groups.
Hypertension in Patients With Peripheral Artery Disease: An Updated Literature Review.
Abraham A, Mojaddedi S, Loseke I, Bray C Cureus. 2024; 16(6):e62246.
PMID: 39006738 PMC: 11245047. DOI: 10.7759/cureus.62246.
Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.
Brassington K, Selemidis S, Bozinovski S, Vlahos R Clin Sci (Lond). 2022; 136(6):405-423.
PMID: 35319068 PMC: 8968302. DOI: 10.1042/CS20210835.
Nezu T, Hosomi N J Atheroscler Thromb. 2020; 27(10):1023-1035.
PMID: 32863299 PMC: 7585913. DOI: 10.5551/jat.RV17044.
Kim C, Wang S, Park J, Jung K, Yoon Y, Lee S J Atheroscler Thromb. 2018; 25(11):1137-1148.
PMID: 29515050 PMC: 6224202. DOI: 10.5551/jat.42861.